May 9 |
Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript
|
May 9 |
Oncternal Therapeutics GAAP EPS of -$2.83 beats by $0.05, revenue of $0.57M beats by $0.44M
|
May 9 |
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
|
May 8 |
Oncternal Therapeutics Q1 2024 Earnings Preview
|
May 2 |
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
|
Apr 18 |
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
|
Apr 2 |
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
|
Mar 15 |
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
|
Mar 10 |
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
|
Mar 8 |
Oncternal Therapeutics files for mixed shelf offering
|